Abstracts tagged "Disease Activity"

Abstract Number: 418 • 2015 ACR/ARHP Annual Meeting
Relationship of Race, Ethnicity, and Outcomes in Pediatric Localized Scleroderma: Possible Differences in Disease Activity
Kaveh Ardalan¹, Nicole Hershey¹, Jonathan Yabes², Kathryn S. Torok¹ and The CARRA Registry Investigators, ¹Pediatric Rheumatology, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA, ²Department of Medicine, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Pediatric localized scleroderma (LS) is an autoimmune skin and soft tissue disease that causes morbidity via progressive skin fibrosis and extracutaneous manifestations (ECMs), such…
Abstract Number: 666 • 2015 ACR/ARHP Annual Meeting
Disease Activity Indices and Body Mass Index: Cross-Sectional Analysis of a Large Psoriatic Arthritis Cohort
Umut Kalyoncu¹, Ozun BayndÄ±r¹, Barış Yılmazer¹, Ediz Dalkilic², Kenan Aksu¹, Mustafa Ferhat Oksuz¹, E.Figen Tarhan¹, Meryem Can¹, Orhan Kucuksahin¹, Gezmis Kimyon¹, Lutfi Akyol¹, Ahmet Mesut Onat¹, Bunyamin Kisacik¹, Abdulsamet Erden¹, Ahmet Omma¹, Duygu Ersozlu Bakirli¹, Cem Ozisler¹, Emel Gonullu¹, Seval Pehlevan¹, Dilek Solmaz¹, Muhammet Cinar¹, Gozde Cetin¹, Abdurrahman Tufan¹, Muge Aydin Tufan¹, Levent Kilic¹, Sukran Erten¹, Timucin Kasifoglu¹, Senol Kobak¹, Soner Senel¹, Servet Akar¹, Metin Ozgen¹, Esen Kasapoglu-Gunal¹, Veli Yazisiz¹, Sedat Yılmaz¹, Salim Donmez¹, Ä°smail Dogan¹, Hamide Kart Koseoglu¹, Funda Erbasan¹, Fatih Yildiz¹, Cemal Bes¹, Ayse Balkarli¹, Ali Sahin¹, Rıdvan Mercan¹, Fatoş Arslan¹, Atalay Dogru¹, Salih Pay¹, Sule Yavuz¹, Necati Cakir¹, Yasemin Kabasakal¹ and Sibel Z. Aydin¹, ¹PsART study group, Ankara, Turkey, ²Department of Rhematology, Uludag University Faculty of Medicine, Bursa, Turkey
Background/Purpose: Well known comorbidities of Psoriatic arthritis (PsA) such as cardiovascular disease, metabolic syndrome and diabetes mellitus are closely related with body mass index (BMI).…
Abstract Number: 1070 • 2015 ACR/ARHP Annual Meeting
CD 14(C-159T) Polymorphism and Soluble CD14 Are Associated with Increased Disease Activity and Nephritis in SLE
Sarit sekhar Pattanaik¹, Aditya kumar Panda², Rashmi ranjan Sahoo¹, Rina Tripathy³ and Bidyut kumar Das¹, ¹Medicine, SCB Medical College, Cuttack, India, ²Centre for Life science, Central University of Jharkand, Ranchi, India, ³Biochemistry, SCB Medical College, Cuttack, India
Background/Purpose: Cluster of differentiation 14 (CD14) plays an important role in innate immune system as a co-receptor in TLRs (2, 4, 7 and 9) signaling.…
Abstract Number: 1738 • 2015 ACR/ARHP Annual Meeting
Assessing the Validity of the Multi-Biomarker Disease Activity Assay in Patients with Psoriatic Arthritis
Tristan Boyd¹, Doquyen H. Huynh¹, P. Scott Eastman², Ferhan Qureshi³, Eric H. Sasso⁴, Rebecca J. Bolce⁴, Joshua Hillman⁵, David L. Boyle⁶ and Arthur Kavanaugh⁷, ¹Rheumatology, University of California San Diego, La Jolla, CA, ²Crescendo Bioscience, South San Francisco, CA, ³Crescendo Bioscience, Inc., South San Francisco, CA, ⁴Crescendo Bioscience Inc., South San Francisco, CA, ⁵Div of Rheum, UCSD School of Medicine, La Jolla, CA, ⁶Division of Rheumatology, Allergy and Immunology, University of California, San Diego, La Jolla, CA, ⁷University of California, San Diego School of Medicine, LaJolla, CA
Background/Purpose: Considerable heterogeneity across clinical domains of psoriatic arthritis (PsA) can make assessment of disease activity challenging. As a result, there has been interest in…
Abstract Number: 2487 • 2015 ACR/ARHP Annual Meeting
Clinical Practices Participating in a Quality Improvement Project Make Progress in Implementing Population Management
Erin Arnold¹, William Arnold¹, James Bower², Douglas Conaway³, J. Timothy Harrington², Drew Johnson⁴, James Mossell⁵, Joy Schechtman⁶ and Anne Winkler⁷, ¹Orthopedics and Rheumatology of the North Shore, Skokie, IL, ²Joiner Associates LLC, Madison, WI, ³Rheumatology/Medicine, Carolina Health Specialists, Myrtle Beach, SC, ⁴Crescendo Bioscience, Inc., South San Francisco, CA, ⁵Arthritis and Osteo Center of South Georgia, Tifton, GA, ⁶Sun Valley Arthritis Center LTD, Peoria, AZ, ⁷Rheumatology, Winkler Medical Practice LLC, Springfield, MO
Background/Purpose: Population management (PM) offers a promising approach to providing Treat-to-Target (T2T) care for rheumatoid arthritis (RA). PM depends on providing standardized, on-time disease activity…
Abstract Number: 2638 • 2015 ACR/ARHP Annual Meeting
Multiple Psychosocial Factors Influence Subjective Assessments of Disease Activity in Rheumatoid Arthritis
Ying L. Liu¹, Joan M. Bathon^2,3 and Jon T. Giles⁴, ¹Internal Medicine, Columbia University Medical Center, New York, NY, ²Medicine, Columbia University, College, New York, NY, ³Rheumatology, Columbia University College of Physicians & Surgeons, New York, NY, ⁴Division of Rheumatology, Columbia University, College of Physicians & Surgeons, New York, NY
Background/Purpose: Measuring disease activity in rheumatoid arthritis (RA) is important in evaluating efficacy of treatments, but many tests are subjective and lead to discordance in…
Abstract Number: 2884 • 2015 ACR/ARHP Annual Meeting
Epidemiological Parameters Affecting Therapeutic Response in Psoriatic Arthritis Patients
Michail P. Migkos¹, George Somarakis², Evripidis Kaltsonoudis³, Theodora E. Markatseli⁴, Paraskevi V. Voulgari^5,6 and Alexandros A. Drosos⁷, ¹Rheumatology Clinic, Department of Internal Medicine, Medical School, University of Ioannina, 45110, Fellow in Rheumatology, Ioannina, Greece, ²Rheumatology Clinic, Department of Internal Medicine, Medical School, University of Ioannina, 45110, University of Ioannina, Rheumatology Clinic, Ioannina, Greece, ³Rheumatology Clinic, Department of Internal Medicine, Rheumatologist, Ioannina, Greece, ⁴Rheumatology Clinic, Department of Internal Medicine, Fellow in Rheumatology, Ioannina, Greece, ⁵Rheumatology Clinic, Department of Internal Medicine, Assistant Professor of Rheumatology, Ioannina, Greece, ⁶Rheumatology Clinic, Department of Internal Medicine, Medical School, University of Ioannina, 45110, Assistant Professor of Rheumatology, Ioannina, Greece, ⁷Rheumatology Clinic, Department of Internal Medicine, Medical School, University of Ioannina, 45110, Professor of Medicine/Rheumatology, Ioannina, Greece
Background/Purpose: Published data have shown that epidemiological parameters such as Body Mass Index (BMI), gender and disease duration may affect the therapeutic response in psoriatic…
Abstract Number: 3224 • 2015 ACR/ARHP Annual Meeting
Salivary IL-1 Alpha and IL-1 Beta Levels Are Associated with Oral Mucosal Activity in Behcet’s Disease
Nilufer Alpay Kanitez¹, Bahtiyar Toz¹, Feyza Berktas¹, Sertan Ergun², Meltem Koray², Nuray Gurel Polat³, Burak Erer¹ and Ahmet Gül¹, ¹Department of Internal Medicine, Division of Rheumatology, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, ²Department of Oral Medicine, Istanbul University, Faculty of Dentistry, Istanbul, Turkey, ³Department of Microbiology, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey
Background/Purpose: Recurrent oral aphthous ulcers are the common manifestation of the Behçet's disease (BD), and they are indistinguishable from ulcers of recurrent aphthous stomatitis (RAS).…
Abstract Number: 427 • 2015 ACR/ARHP Annual Meeting
The Impact of Biologic Agent Initiation after 1 Versus 2 Prior Csdmards in Patients with Rheumatoid Arthritis
Dimitrios A. Pappas^1,2, Jenny Griffith³, Chitra Karki², Mei Liu⁴, Joel M. Kremer⁵, Arijit Ganguli³ and Jeffrey D. Greenberg^2,6, ¹Columbia University, New York, NY, ²Corrona, LLC, Southborough, MA, ³AbbVie Inc., North Chicago, IL, ⁴352 Turnpike Rd, Corrona, LLC, Southborough, MA, ⁵Albany Medical College and The Center for Rheumatology, Albany, NY, ⁶NYU School of Medicine, New York, NY
Background/Purpose: Patients with Rheumatoid Arthritis (RA) who don’t respond to conventional synthetic disease modifying anti-rheumatic drugs (csDMARDs) should be treated with biologic agents(1). The objective…
Abstract Number: 668 • 2015 ACR/ARHP Annual Meeting
Pasdas, Cpdai and MDA Evolution in the First 6 Months after Diagnosis of Early Psoriatic Arthritis Patients: Results of the Depar Study
Jolanda Luime¹, Ilja Tchetverikov², Marijn Vis³, Cathelyne Appels⁴, Wiebo van der Graaff⁵, Josien Veris⁶, Andreas Gerards⁷, Hans van Groenendaal⁸, Mark Kok⁹, Lindy-Anne Korswagen¹⁰, Cor Stolk¹¹ and Cicero, ¹Department of Rheumatology, Erasmus Medical Centre, Rotterdam, Netherlands, ²Albert Schweitzer Ziekenhuis, Dordrecht, Netherlands, ³Rheumatology, ErasmusMC, Rotterdam, Netherlands, ⁴Rheumatology, Amphia Hospital, Breda, Netherlands, ⁵Rheumatology, Rivas hospital, Gorinchem, Netherlands, ⁶Rheumatology, Reumazorg Zuid West Nederland, Goes, Netherlands, ⁷Rheumatology, Vlietland Hospital, Schiedam, Netherlands, ⁸Rheumatology, Reumazorg Zuid West Nederland, Roosendaal, Netherlands, ⁹Maasstadweg 21, Maasstad Ziekenhuis, Rotterdam, Netherlands, ¹⁰Rheumatology, Sint Fransicus Gasthuis, Rotterdam, Netherlands, ¹¹-, Patient Partner, Bunnink, Netherlands
Background/Purpose: Several disease activity measures were developed for use in psoriatic arthritis (PsA) . Little data is available on their performance in usual care. This…
Abstract Number: 1072 • 2015 ACR/ARHP Annual Meeting
Baseline Gene Expression Profiles in 1760 Patients from Two Phase III Trials of BAFF/BLyS Blockade in SLE
Robert W Hoffman¹, Joan T Merrill², Marta E. Marta Alarcón Riquelme³, Michelle Petri⁴, Ernst R Dow⁵, Eric Nantz⁶, Laura K Nisenbaum⁵, Krista M Schroeder⁶, Wendy J Komocsar⁶, Narayanan B Perumal⁵, Matthew D Linnik⁶, Guilherme V Rocha⁶ and Richard E Higgs⁶, ¹Immunology-Medical, Eli Lilly and Company, Indianapolis, IN, ²OMRF, Oklahoma, OK, ³Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Johns Hopkins Lupus Center, Johns Hopkins University School of Medicine, Baltimore, MD, ⁵Eli Lilly and Company, Indiananpolis, IN, ⁶Eli Lilly and Company, Indianapolis, IN
Background/Purpose: Elevated Type-I interferon (IFN) signature characterizes at least 50% of adults with SLE and has been associated with autoantibodies and more severe disease in…
Abstract Number: 1743 • 2015 ACR/ARHP Annual Meeting
Gender Differences in Ankylosing Spondylitis: Men Derive Greater Benefit from Tumor Necrosis Factor Alpha Inhibitors
Jennifer Mandal¹, Michael M. Ward², Michael Weisman³, Jillian Simard⁴, Matthew A. Brown⁵, MinJae Lee⁶, Mohammad H. Rahbar⁷, John D. Reveille⁸ and Lianne S. Gensler⁹, ¹Medicine, University of California San Francisco, San Francisco, CA, ²NIH/NIAMS, Bethesda, MD, ³Cedars-Sinai Medical Center, Los Angeles, CA, ⁴University of California San Francisco, San Francisco, CA, ⁵The University of Queensland Diamantina Institute, Brisbane, Australia, ⁶Biostatistics/Epidemiology/Research Design (BERD) Core | Center for Clinical and Translational Sciences, University of Texas Health Science Center at Houston, Houston, TX, ⁷The University of Texas Health Science Center at Houston, Houston, TX, ⁸Rheumatology, University of Texas Health Science Center at Houston, Houston, TX, ⁹Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA
Background/Purpose: Ankylosing spondylitis (AS) manifests differently in men and women. Women with AS have less severe radiographic disease, yet tend to report more severe symptoms.…
Abstract Number: 2490 • 2015 ACR/ARHP Annual Meeting
Implementation of Disease Activity Measurement for Rheumatoid Arthritis Patients in an Academic Rheumatology Clinic
Alison Bays¹, Elizabeth R. Wahl², David I. Daikh³, Jinoos Yazdany⁴ and Gabriela Schmajuk⁵, ¹Rheumatology, University of Washington, Seattle, WA, ²Medicine/Rheumatology, San Francisco Veterans Affairs Medical Center, San Francisco, CA, ³Rheumatology, UCSF/VA Medical Center, San Francisco, CA, ⁴Rheumatology, UCSF, SF, CA, ⁵San Francisco VA Medical Center, University of California, San Francisco, San Francisco, CA
Background/Purpose: Current recommendations for optimal rheumatoid arthritis (RA) management include routine assessment of disease activity and adjustment of medication to achieve remission or low disease…
Abstract Number: 2643 • 2015 ACR/ARHP Annual Meeting
Decreased Pain Level with Aging Leads to Underestimation of Disease Activity in Rheumatoid Arthritis
Yong Gil Hwang¹, Juan (June) Feng², Heather Eng³, Jason Lyons⁴, Anthony Fabio⁵ and Larry W. Moreland⁶, ¹Department of Medicine, University of Pittsburgh, Pittsburgh, PA, ²Epidemiology Data Center, University of Pittsburgh, Graduate School of Public Health, Pittsburgh, PA, ³Epidemiology, Univ of Pittsburgh, Pittsburgh, PA, ⁴School of Public Health, Department of Epidemiology, University of Pittsburgh, Pittsburgh, PA, ⁵Department Of Epidemiology, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA, ⁶Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Rheumatoid arthritis (RA) is most prevalent in those who are 60 years of age or older. It has not been clearly established whether…
Abstract Number: 2901 • 2015 ACR/ARHP Annual Meeting
Anti-dsDNA Antibodies Measured By Chemiluminescent Immunoassay Show Strong Association with Active Lupus Nephritis
Gabriella Lakos¹, John G. Hanly², Peter Martis¹, Chelsea Bentow¹, Milagros Garcia³, Odette Viñas³, Gerard Espinosa⁴, Ricard Cervera⁴ and Michael Mahler⁵, ¹Research, Inova Diagnostics, San Diego, CA, ²Rheumatology, Division of Rheumatology, Capital Health and Dalhousie University, Halifax, NS, Canada, ³Immunology, Hospital Clinic of Barcelona, Barcelona, Spain, ⁴Department of Autoimmune Diseases, Hospital Clínic, Barcelona, Spain, ⁵Inova Diagnostics, San Diego, CA
Background/Purpose: Anti-dsDNA antibodies support the diagnosis of systemic lupus erythematosus (SLE), and their quantification is useful for the assessment of lupus nephritis (LN) and the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].